BOSTON SCIENTIFIC CORPORATION

The EP PASSION project, initiated in 2017, transitioned the Solia study from traditional long-term clinical trials to using real-world data (RWD) for cardiac lead safety assessments. The study validated the feasibility of RWD methodologies, showing no significant difference in identifying lead complications compared to traditional methods. The Solia S lead demonstrated a 97.19% complication-free rate at 5 years post-implant, confirming its long-term safety and reliability. This approach reduces costs and study duration, paving the way for more efficient post-market device evaluations.

The global eHealth market is projected to grow from USD 97.4 billion in 2023 to USD 393.6 billion by 2032, at a CAGR of 15.4%. eHealth integrates digital technologies for patient care, enhancing data accessibility, remote monitoring, and patient-centered care. Key trends include telemedicine, AI, wearable devices, and personalized medicine, revolutionizing healthcare delivery and improving outcomes.

The cardiac implants market, valued at USD 38.1 billion in 2023, is projected to reach USD 79.2 billion by 2032, growing at a CAGR of 8.5%. Factors driving growth include the rising prevalence of cardiovascular diseases, an aging population, and advancements in medical technology. Governments and regulatory bodies are supporting market growth through investments and stringent regulations, enhancing patient confidence in cardiac implants.

The Image-guided Therapy Market, 2024-2029 report by ResearchAndMarkets.com highlights the rapid growth of the IGT market driven by minimally invasive procedures, technological advancements, and precision medicine. The market is segmented into capital equipment, medical devices, solutions, and clinical applications like oncology, cardiology, neurosurgery, urology, and orthopedics. Key companies include Elekta, Boston Scientific Corporation, Koninklijke Philips N.V., GE HealthCare, and Ziehm Imaging.

VIVA Foundation announces results from VIVA24 conference, highlighting 8 late-breaking clinical trials on vascular medicine advancements, including limb salvage rates, durability of percutaneous transmural arterial bypass, retrievable scaffold therapy, sirolimus-coated balloon angioplasty, and diversity in clinical trials.

VIVA symposium highlights 9 late-breaking clinical trials, including LIFE-BTK's 2-year results showing Esprit BTK Drug-Eluting Resorbable Scaffold's superior efficacy over PTA in treating CLTI, and the Shockwave Javelin Peripheral IVL catheter's success in reducing target lesion stenosis without perforations or embolization. Other trials demonstrated the safety and effectiveness of IVL, laser-based IVL, and directional atherectomy with drug-coated balloons in treating calcified lesions, and the efficacy of transcarotid artery revascularization and mechanical thrombectomy for DVT and PE.

Boston Scientific announced ACURATE neo2 Aortic Valve System results in ACURATE IDE trial, showing 16.16% composite rate of all-cause mortality, stroke, or rehospitalization at one year, not meeting non-inferiority criteria. Post-hoc analysis identified under-expanded valves, suggesting procedural optimization importance for TAVR outcomes.

The global drug device combination products market is projected to grow from $114.8B in 2023 to $158.7B by 2030, driven by tech advancements, regulatory support, and chronic disease prevalence. Key segments include transdermal patches and inhalers, with significant growth in emerging markets like China.